Vectura Group

Philip Morris International Inc. (PMI) Presents at the 2021 Morgan Stanley Virtual Global Consumer & Retail Conference

Retrieved on: 
Wednesday, December 1, 2021
Tobacco, Retail, Other Retail, Private Securities Litigation Reform Act, IQOS, Judgement, Sale, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Technology, Vectura Group, Form, Recurrence, Smoke, Tobacco, CCAA, EPS, Philip Morris International, COVID-19, Information, Smoker, City, Lists of disasters, Intellectual property, Research, Adult, MRTP, Marketing, RBH, Knowledge, Tobacco industry, FDA, Semiconductor, Public health, Achievement, Privacy, Travel, Food, PMI, Cryptocurrency, Risk management

Applying prevailing exchange rates to anticipated 2021 full-year adjusted diluted EPS would imply an estimated unfavorable impact of around $0.40 per share.

Key Points: 
  • Applying prevailing exchange rates to anticipated 2021 full-year adjusted diluted EPS would imply an estimated unfavorable impact of around $0.40 per share.
  • Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.
  • This press release, the presentation and related discussion contain projections of future results and other forward-looking statements.
  • PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties.

Awakn Life Sciences Strengthens Executive Leadership Team

Retrieved on: 
Tuesday, November 30, 2021
News, Perception, EMEA, Ernst, Review, CEO, Special-purpose acquisition company, SEDAR, Phrase, Anglo American plc, Forward-looking statement, Vectura Group, Company, Group, Anglo-Americans, Therapy, Kate, CFO, Ernst & Young, Public opinion, Intention, FSE, Gilead Sciences, NEO, Pharmaceutical industry, Management, Audit

Kate Butler to Be Appointed CFO; Jonathan Held, Current CFO, to Be Appointed Chief Business Officer

Key Points: 
  • Ms. Butler joins Awakn from Vectura Group plc, where she was the Group Financial Controller leading the team's strategic, finance and M&A activity.
  • We are delighted to welcome another skilled executive to our leadership team."
  • Kate Butler, newly appointed CFO commented, "I am very excited to be joining an already talented and impressive senior leadership team and board at Awakn.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.

Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer

Retrieved on: 
Thursday, November 18, 2021
Patient, Master of Business Administration, SVKM's NMIMS, CE, Head, Forward-looking statement, Vectura Group, Acquisition, Company, Shire (pharmaceutical company), Wharton School of the University of Pennsylvania, University, Leadership, Inhalation, Therapy, Baxter, Shire, GLOBE, CFO, Salomon Brothers, Kellogg School, Hypertensive emergency, Northwestern University, NASDAQ, Business administration, Ovation Pharmaceuticals, Pharmaceutical industry, Management

DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the Company), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced theappointment of Barry Deutsch as chief financial officer effective November 15, 2021.

Key Points: 
  • DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the Company), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced theappointment of Barry Deutsch as chief financial officer effective November 15, 2021.
  • Barry is a seasoned financial executive who brings decades of experience in business development and corporate finance having worked with both public and private life science companies and in investment banking.
  • Most recently, Mr. Deutsch was CFO and, before that, vice president of business development, at Xeris Pharmaceuticals, Inc. (NASDAQ: XERS).
  • Mr. Deutsch added, Im excited to be joining Aerami Therapeutics.

Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors

Retrieved on: 
Thursday, November 11, 2021
Therapy, Southern New Hampshire University, NASDAQ, Rivier University, Vectura Group, CE, Senior, Forward-looking statement, Federal Food, Drug, and Cosmetic Act, GLOBE, Hypertensive emergency, Accounting, Inhalation, Pharmaceutical industry, Management

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced theappointment of Darlene DeptulaHicks, Chief Financial Officer of F-star Therapeutics, Inc., to its board of directors and chair of the audit committee.

Key Points: 
  • DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced theappointment of Darlene DeptulaHicks, Chief Financial Officer of F-star Therapeutics, Inc., to its board of directors and chair of the audit committee.
  • I am delighted to welcome Darlene to our board of directors, said Steve Thornton, chief executive officer of Aerami.
  • Ms. Deptula-Hicks biopharmaceutical industry experience spans more than 30 years and includes serving in finance executive leadership positions and on the board of directors.
  • Aerami undertakes no obligation to update any forward-looking statements for any reason.

Philip Morris International Inc. (PMI) Presents at the 2021 Barclays Global Consumer Staples Conference; Reaffirms 2021 Full-Year Reported Diluted EPS Forecast Range of $5.76 to $5.86

Retrieved on: 
Wednesday, September 8, 2021
Tobacco, Retail

The full-year forecast continues to assume third-quarter reported diluted EPS in a range of $1.50 to $1.55, now with a favorable currency impact, at prevailing exchange rates, of around $0.03 per share (versus $0.04 previously).

Key Points: 
  • The full-year forecast continues to assume third-quarter reported diluted EPS in a range of $1.50 to $1.55, now with a favorable currency impact, at prevailing exchange rates, of around $0.03 per share (versus $0.04 previously).
  • Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.
  • This press release, the presentation and related discussion contain projections of future results and other forward-looking statements.
  • In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements.

Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension

Retrieved on: 
Wednesday, August 25, 2021
Cancer, Muscle tissue, Blood pressure, Hypertensive emergency, Blood, PAH, Dry-powder inhaler, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vasodilation, Inhalation, CE, Disease, Food, Therapy, Heart, Forward-looking statement, Cough, Â, Patient, Toxicity, FDA, Degenerative disease, Federal Food, Drug, and Cosmetic Act, Woman, Pulmonary hypertension, Vectura Group, Pharmaceutical industry

Food and Drug Administration(FDA) has granted the company orphan drug designation for imatinib for treatment of patients with pulmonary arterial hypertension (PAH).

Key Points: 
  • Food and Drug Administration(FDA) has granted the company orphan drug designation for imatinib for treatment of patients with pulmonary arterial hypertension (PAH).
  • AER 901, Aeramis drug-device combination product candidate for inhaled imatinib for the treatment of PAH is currently in a Phase 1 trial with completion targeted for the end of 2021.
  • The Fox achieves deep lung deposition by administering drug only during inhalation and controlling the flow rate and volume during inspiration.
  • Aerami undertakes no obligation to update any forward-looking statements for any reason.

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Retrieved on: 
Wednesday, August 4, 2021
Equity, Law, Articles, Settlor, Trust law, Vectura Group, Trustee

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Retrieved on: 
Wednesday, August 4, 2021
Equity, Law, Articles, Settlor, Trust law, Vectura Group, Trustee

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Retrieved on: 
Tuesday, August 3, 2021
Equity, Law, Articles, Settlor, Trust law, Vectura Group, Trustee

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Retrieved on: 
Friday, July 30, 2021
Equity, Law, Articles, Settlor, Trust law, Vectura Group, Trustee

Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc

Key Points: 
  • Form 8.3 - The Vanguard Group, Inc.: Vectura Group plc
    Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.